Hosted on MSN22h
Viking Therapeutics begins VK2735 Phase II trial for obesity treatment
Scheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.
Viking Therapeutics: Strategic Positioning and Promising Development of Oral 2735 Drive Buy Rating
J.P. Morgan analyst Hardik Parikh has maintained their bullish stance on VKTX stock, giving a Buy rating today.Stay Ahead of the ...
Viking Therapeutics’ Promising Phase 2 Trial and Competitive Edge Justify Buy Rating
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target ...
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...
Kiplinger2mon
Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data
The data released by Viking showed that adults taking the highest ... effective maintenance of weight control," said Viking CEO Brian Lian, Ph.D., in a statement. Profit and prosper with the ...
Hosted on MSN2mon
Viking Therapeutics’ weight-loss pill shows ‘great outcome’ in trial
Viking Therapeutics Inc. cheered analysts Monday ... activity at doses of up to 100 mg daily,” Viking Chief Executive Brian Lian said in prepared remarks. “We believe the durable effects ...
Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...